Reuters: Health
Swiss-listed drugmaker ObsEva said on Thursday it is abandoning the current program for its drug prospect nolasiban after the agent aimed at boosting pregnancy following in-vitro fertilization (IVF) failed a late-stage study in Europe.
No comments:
Post a Comment